Aurinia Pharmaceuticals (AUPH) Operating Leases (2020 - 2026)

Aurinia Pharmaceuticals has reported Operating Leases for 7 years, with the latest figure at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 40.07% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 40.07% YoY), and the FY2025 full-year result was $4.9 million, down 14.68% from the prior year.
• Operating Leases for Q1 2026 stood at $3.9 million, down from $4.9 million in the prior quarter.
• The five-year high for Operating Leases was $8.6 million in Q1 2022, with the low at $3.9 million in Q1 2026.
• Historically, Operating Leases has averaged $6.7 million across 5 years, with a median of $7.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases rose 5.04% — and 2026, when it plunged 40.07%.
• Aurinia Pharmaceuticals' Operating Leases stood at $7.2 million in 2022, then slipped by 8.7% to $6.5 million in 2023, then slipped by 12.05% to $5.7 million in 2024, then dropped by 14.68% to $4.9 million in 2025, then slipped by 19.59% to $3.9 million in 2026.
• The last three Operating Leases figures came in at $3.9 million (Q1 2026), $4.9 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.